authors Abdelrahim, Maen Mu, Fan Seshasayee, Shravanthi M Hernandez, Sairy Tran, Nguyen H Esmail, Abdullah Kim, Richard D Arora, Sukeshi Patel Arshad, Junaid Kournoutas, Ioannis A O'Donnell, Conor D Totev, Todor I Tan, Amie
Keywords atezolizumab bevacizumab clinical effectiveness healthcare resource utilization hepatocellular carcinoma immunotherapy